Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer

International Journal of Cancer

Volumn 124, Issue 6, 2009, Pages 1429-1439

  Yagi, Hiroshi ^a   Yotsumoto, Fusanori ^b   Sonoda, Kenzo ^a   Kuroki, Masahide ^b   Mekada, Eisuke ^c   Miyamoto, Shingo ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

CRM197; EGFR; HB EGF; Ovarian cancer; Paclitaxel

Indexed keywords

DIPHTHERIA TOXOID CRM197; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; BACTERIAL PROTEIN; CELL SURFACE RECEPTOR; CRM197 (NON TOXIC VARIANT OF DIPHTHERIA TOXIN); CRM197 (NON-TOXIC VARIANT OF DIPHTHERIA TOXIN); DIPHTHERIA TOXIN; HEPARIN ANTAGONIST; HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PRIMER DNA; RNA; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; OVARY TUMOR; PATHOLOGY; PLASMID; POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BACTERIAL PROTEINS; CELL SURVIVAL; DIPHTHERIA TOXIN; DNA PRIMERS; FEMALE; HEPARIN ANTAGONISTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OVARIAN NEOPLASMS; PACLITAXEL; PLASMIDS; POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; RNA, NEOPLASM; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 60549113956     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24031     Document Type: Article

References (60)

1. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
2. Sarosy G, Reed E. Taxol dose intensification and its clinical implications. J Natl Med Assoc 1993;85:427-31.
3. Rowinsky EK. Update on the antitumor activity of paclitaxel in clinical trials. Ann Pharmacother 1994;28(5 Suppl):S18-S22.
4. Fan M, Chambers TC. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Update 2001;4:253-67.
5. Okano J, Rustgi AK. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem 2001;276:19555-64.
6. Riese DJ, II, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998;20:41-8.
7. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991;251:936-9.
8. Izumi Y, Hirata M, Hasuwa H, Iwamoto R, Umata T, Miyado K, Tamai Y, Kurisaki T, Sehara-Fujisawa A, Ohno S, Mekada E. A metalloprotease-disintegrin MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane- anchored heparin-binding EGF-like growth factor. EMBO J 1998;17:7260-72.
9. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003;17:7-30.
10. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402:884-8.
11. Takenobu H, Yamazaki A, Hirata M, Umata T, Mekada E. The stressand inflammatory cytokine-induced ectodomain shedding of heparinbinding epidermal growth factor-like growth factor is mediated by p38 MAPK, distinct from the 12-O-tetradecanoylphorbol-13-acetateand lysophosphatidic acid-induced signaling cascades. J Biol Chem 2003;278:17255-62.
12. Goishi K, Higashiyama S, Klagsbrun M, Nakano N, Umata T, Ishikawa M, Mekada E, Taniguchi N. Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol Biol Cell 1995;6:967-80.
13. Dethlefsen SM, Raab G, Moses MA, Adam RM, Klagsbrun M, Freeman MR. Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin-binding EGF-like growth factor independently of protein kinase C. J Cell Biochem 1998; 69:143-53.
14. Tanida S, Joh T, Itoh K, Kataoka H, Sasaki M, Ohara H, Nakazawa T, Nomura T, Kinugasa Y, Ohmoto H, Ishiguro H, Yoshino K, et al. The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells. Gastroenterology 2004;127:559-69.
15. Gechtman Z, Alonso JL, Raab G, Ingber DE, Klagsbrun M. The shedding of membrane-anchored heparin-binding epidermal-like growth factor is regulated by the Raf/mitogen-activated protein kinase cascade and by cell adhesion and spreading. J Biol Chem 1999;274: 28828-35.
16. Iwamoto R, Mekada E. Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev 2000;11:335-44.
17. Nanba D, Higashiyama S. Dual intracellular signaling by proteolytic cleavage of membrane-anchored heparin-binding EGF-like growth factor. Cytokine Growth Factor Rev 2004;15:13-9.
18. Nishi E, Klagsbrun M. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a mediator of multiple physiological and pathological pathways. Growth Factors 2004;22:253-60.
19. Miyamoto S, Yagi H, Yotsumoto F, Kawarabayashi T, Mekada E. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci 2006;97: 341-7.
20. Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M, Kanoh H, Nakano H, et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004;64:5720-7.
21. Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, Iwamoto R, Mekada E, Nakano H. Clinical significance of heparinbinding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer 2005;92:1737-45.
22. Mitamura T, Higashiyama S, Taniguchi N, Klagsbrun M, Mekada E. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 1995;270:1015-9.
23. Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E, Nakano H. Clinical significance of heparin-binding epidermal growth factorlike growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 2005;11: 4783-92.
24. Uchida T, Pappenheimer AM, Jr, Greany R. Diphtheria toxin and related proteins. I. Isolation and properties of mutant proteins serologically related to diphtheria toxin. J Biol Chem 1973;248:3838-44.
25. Yamazaki S, Iwamoto R, Saeki K, Asakura M, Takashima S, Yamazaki A, Kimura R, Mizushima H, Moribe H, Higashiyama S, Endoh M, Kaneda Y, et al. Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities. J Cell Biol 2003; 163:469-75.
26. Hasuwa H, Kaseda K, Einarsdottir T, Okabe M. Small interfering RNA and gene silencing in transgenic mice and rats. FEBS Lett 2002; 532:227-30.
27. Okugawa K, Kobayashi H, Hirakawa T, Sonoda T, Ogura T, Nakano H. In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo. J Cancer Res Clin Oncol 2004; 130:178-86.
28. Iwamoto R, Higashiyama S, Mitamura T, Taniguchi N, Klagsbrun M, Mekada E. Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity. EMBO J 1994;13:2322-30.
29. Higashiyama S, Iwamoto R, Goishi K, Raab G, Taniguchi N, Klagsbrun M, Mekada E. The membrane protein CD9/DRAP27 potentiates the juxtacrine growth factor actiovity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol 1995;128:929-38.
30. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res 1995;55:4623-6.
31. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996;56:1851-4.
32. McCarthy SA, Samuels ML, Pritchard CA, Abraham JA, McMahon M. Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev 1995;9:1953-64.
33. Wang F, Liu R, Lee SW, Sloss CM, Couget J, Cusack JC. Heparinbinding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 2007; 26:2006-16.
34. Goechtman Z, Alonso JL, Raab G, Ingber DE, Klagsbrun M. The shedding of membrane-anchored heparin-binding epidermal-like growth factor is regulated by the Raf/mitogen-activated protein kinase cascade and by cell adhesion and spreading. J Biol Chem 1999; 274:28828-35.
35. Umata T, Hirata M, Takahashi T, Ryu F, Shida S, Takahashi Y, Tsuneoka M, Miura Y, Masuda M, Horiguchi Y, Mekada E. A dual signaling cascade that regulates the ectodomain shedding of heparinbinding epidermal growth factor-like growth factor. J Biol Chem 2001;276:30475-82.
36. Lin J, Hutchinson L, Gaston SM, Raab G, Freeman MR. BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparinbinding EGF-like growth factor: a unique role for proHB-EGF in cell survival regulation. J Biol Chem 201;267:30127-32.
37. Nanba D, Mammoto A, Hashimoto K, Higashiyama S. Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 2003;163:489-502.
38. Kinugasa Y, Hieda M, Hori M, Higashiyama S. The carboxyl-terminal fragment of pro-HB-EGF reverses Bcl6-mediated gene repression. J Biol Chem 2007;282:14797-806.
39. Yeyati PL, Shaknovich R, Boterashvili S, Li J, Ball HJ, Waxman S, Nason-Burchenal K, Dmitrovsky E, Zelent A, Licht JD. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene 1999;18:925-34.
40. McConnell MJ, Chevallier N, Berkofsky-Fessler W, Giltnane JM, Malani RB, Staudt LM, Licht JD. Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol 2003;23:9375-88.
41. Ferńandez de Mattos S, Essafi A, Soeiro I, Pietersen AM, Birkenkamp KU, Edwards CS, Martino A, Nelson BH, Francis JM, Jones MC, Brosens JJ, Coffer PJ, et al. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol 2004;24:10058-71.
42. Chattopadhyay A, Tate SA, Beswick RW, Wagner SD, Ko Ferrigno P. A peptide aptamer to antagonize BCL-6 function. Oncogene 2006; 25:2223-33.
43. Bardelli A, Longati P, Albero D, Goruppi S, Schneider C, Ponzetto C, Comoglio PM. HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO J 1996;15:6205-12.
44. Froesch BA, Takayama S, Reed JC. BAG-1L protein enhances androgen receptor function. J Biol Chem 1998;273:11660-6.
45. Wang HG, Takayama S, Rapp UR, Reed JC. Bcl-2 interacting protein BAG-1, binds to and activates the kinase. Raf-1. Proc Natl Acad Sci USA 1996;93:7063-8.
46. Schneikert J, Heubner S, Martin E, Cato AC. A nuclear action of the eukaryotic cochaperone RAP46 in downregulation of glucocorticoid receptor activity. J Cell Biol 1999;146:929-40.
47. Datta SR, Ranger AM, Lin MZ, Sturgill JF, Ma YC, Cowan CW, Dikkes P, Korsmeyer SJ, Greenberg ME. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell 2002;3:631-43.
48. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, Tasaka K, Murata Y. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002;277:33490-500.
49. Yang JY, Michod D, Walicki J, Widmann C. Surviving the kiss of death. Biochem Pharmacol 2004;68:1027-31.
50. Ohmichi M, Hayakawa J, Tasaka K, Kurachi H, Murata Y. Mechanisms of platinum drug resistance. Trends Pharmacol Sci 2005;26: 113-6.
51. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001;21:893-901.
52. Park HS, Kim MS, Huh SH, Park J, Chung J, Kang SS, Choi EJ. Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J Biol Chem 2002;277:2573-8.
53. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC. Focus on epithelial ovarian cancer. Cancer Cell 2004;5:19-24.
54. Siddik ZH. Cysplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
55. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T, Murata Y. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 2000;60:5988-94.
56. Lopez AM, Pegram MD, Slamon DJ, Landaw EM. A model-based approach for assessing in vivo combination therapy interactions. Proc Natl Acad Sci USA 1999;96:13023-8.
57. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-49.
58. Schmidt M, Lichtner RB. EGF receptor targeting in therapy-resistant human tumors. Drug Resist Update 2002;5:11-18.
59. Shimura T, Kataoka H, Ogasawara N, Kubota E, Sasaki M, Tanida S, Joh T. Suppression of proHB-EGF carboxy-terminal fragment nuclear translocation: a new molecular target therapy for gastric cancer. Clin Cancer Res 2008;14:3956-65.
60. Buzzi S, Rubboli D, Buzzi G, Buzzi AM, Morisi C, Pironi F. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol Immunother 2004;53:1041-8.